Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality

儿童梅克尔闪烁显像术前用药:泮托拉唑与雷尼替丁在优化扫描质量方面的比较

阅读:1

Abstract

BACKGROUND: The standard method for diagnosing Meckel diverticulum and identifying ectopic gastric mucosa is (99 m)Tc-pertechnetate imaging. Premedication with H(2) receptor antagonists enhances the scan's sensitivity by reducing the washout of (99 m)Tc-pertechnetate activity from the intestinal lumen. OBJECTIVE: After the withdrawal of ranitidine, we compared the efficacy of the proton pump inhibitor pantoprazole as an alternative premedication agent for (99 m)Tc-pertechnetate Meckel diverticulum imaging. MATERIALS AND METHODS: This study assessed the scan quality of 141 children (aged 1 month to 204 months (median = 84 months)) who underwent Meckel scintigraphy over 10 years at a single institution. Before its withdrawal in December 2020, ranitidine was utilized for premedication, while pantoprazole was used thereafter. Therefore, patients were divided into two premedication groups: ranitidine (n = 88) and pantoprazole (n = 53). A high-quality scan was defined as having no (99 m)Tc-pertechnetate activity in the duodenal and other intestinal lumens. The effectiveness of pantoprazole in reducing (99 m)Tc-pertechnetate release in the duodenum and other intestinal lumens was compared to that of ranitidine. Differences in scan quality between the groups were analyzed using the two-proportion Z-test. In patients with positive scans, the lesion-to-background activity ratio of the Meckel diverticulum was measured and compared between the premedication groups. RESULTS: Premedication with pantoprazole resulted in 47.2% of scans showing no (99 m)Tc-pertechnetate release, 37.7% with activity localized either in the duodenum or other intestine, and 15.1% exhibiting activity in both regions. In comparison, ranitidine resulted in 45.5% of scans with no (99 m)Tc-pertechnetate release, 40.9% with activity localized either in the duodenum or other intestine, and 13.6% showing activity in both regions. P-values were not found to be significant in all comparisons. Twelve scans were positive; all patients had Meckel diverticulum confirmed at surgery. For positive scans, the lesion-to-background activity ratio for the Meckel diverticulum was similar between the ranitidine and pantoprazole groups. CONCLUSION: This study demonstrates that pantoprazole is statistically non-inferior to ranitidine regarding scan quality and lesion-to-background activity ratios for Meckel diverticulum detection. Pantoprazole offers a reliable alternative for clinical protocols in the absence of ranitidine.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。